Abstract:Introduction and aim The current SARS-CoV-2 Omicron variant is distinct, compared to parental SARS-CoV-2 and other variant of concern (VOC), in at least two notable extents: 1) is a master of immune evasion but maintains robust angiotensin-converting enzyme 2 (ACE2) binding; and 2) depends more on cell endocytic pathway than other VOC to promote cell entry, leading to significant loss of endogenous mucosal ACE2 for lung protection as well as escape from neutralization antibodies and thus higher infectivity. The Omicron variant is more likely than other VOCs to cause upper airway infection and affects much less in lung distal tissue. People with weakened immune systems and those who had underlying conditions are considered high risk. Taken together the Omicron variant underscores the urgency of exploring effective prophylactic and therapeutic interventions to boost mucosal immunity against Omicron cell entry in upper airways. The study is to offer the potential prophylactic and therapeutic strategies protecting mucosal immunity against breakthrough infections. Patients and methods Based on the viral structure and the mechanisms of its interaction with host cells, we are testing several potential strategies against SARS-CoV-2 infection and its VOC in human lung organoids and humanized mice. The approaches include, but not limited to, using decoy viral particles, decoy host receptors and blockage of host receptor complex, as well as targeting the SARS-CoV-2 conserved non-structured protein regions and interrupting viral genome from which VOC with mutative spike proteins may escape. Results We have observed significant preservation of mucosal ACE2, decreases in viral load, clinical manifestation scores, lung injury scores using recombinant human ACE2 in humanized mice infected with SARS-CoV-2. We also demonstrated a potential prophylactic role of recombinant ACE2 and SARS-CoV-2 varus-like particles as decoys to attenuate the numbers of viral gene copy and cytopathic effects in human lung organoids infected with Delta and Omicron (BA.2) variants. Conclusion The decoy host receptor and decoy virus-like particles have shown promising results that will preserve mucosal host immunity and facilitate the development of effective prophylactic and treatment capability against breakthrough SARS-CoV-2 infections. Grant acknowledgement This work was supported by the Canadian Institutes of Health Research (OV3–170344, SBC-171482 and VS1–175560) to HZ.

Protecting mucosal innate immunity against SARS-CoV-2 variant of concern

Intranasal administration of a recombinant RBD vaccine induces long-term immunity against Omicron-included SARS-CoV-2 variants

Mucosal immunity against SARS-CoV-2 variants of concern including Omicron following vaccination

Improving Nasal Protection for Preventing SARS-CoV-2 Infection

Respiratory mucosal immunity against SARS-CoV-2 following mRNA vaccination

Intranasal SARS-CoV-2 Omicron variant vaccines elicit humoral and cellular mucosal immunity in female mice

Aerosol Inhalation of Chimpanzee Adenovirus Vectors (ChAd68) Expressing Ancestral or Omicron BA.1 Stabilized Pre-Fusion Spike Glycoproteins Protects Non-Human Primates against SARS-CoV-2 Infection

Inhalation of ACE2-expressing lung exosomes provides prophylactic protection against SARS-CoV-2

Mucosal nanobody IgA as inhalable and affordable prophylactic and therapeutic treatment against SARS-CoV-2 and emerging variants

The Modulation of Mucosal Antiviral Immunity by Immunobiotics: Could They Offer Any Benefit in the SARS-CoV-2 Pandemic?

OM-85 Broncho-Vaxom®, a Bacterial Lysate, Reduces SARS-CoV-2 Binding Proteins on Human Bronchial Epithelial Cells

The Papain-like Protease Domain of Severe Acute Respiratory Syndrome Coronavirus 2 Conjugated with Human Beta-Defensin 2 and Co1 Induces Mucosal and Systemic Immune Responses against the Virus

Efficacy of host cell serine protease inhibitor MM3122 against SARS-CoV-2 for treatment and prevention of COVID-19

Two Pan-Sars-cov-2 Nanobodies and Their Multivalent Derivatives Effectively Prevent Omicron Infections in Mice.

Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances to Counter the SARS-CoV-2 Omicron Variant

Mucosal Immunity against SARS-CoV-2 in the Respiratory Tract

Development of a mutant aerosolized ACE2 that neutralizes SARS-CoV-2 in vivo

Cross-protection induced by highly conserved human B, CD4+, and CD8+ T-cell epitopes-based vaccine against severe infection, disease, and death caused by multiple SARS-CoV-2 variants of concern

Influenza virus strains expressing SARS-CoV-2 receptor binding domain protein confer immunity in K18-hACE2 mice

Hacking Commensal Bacteria to Consolidate the Adaptive Mucosal Immune Response in the Gut–Lung Axis: Future Possibilities for SARS-CoV-2 Protection

Study of immunogenicity and efficacy against Omicron BA.5 of recombinant protein-based COVID-19 vaccine delivered by intramuscular and mucosal routes in nonhuman primates